SEC Filing Summary: Corcept Therapeutics Inc. (CORT)
Business Context and Reporting Period
This Form 8-K was filed on June 17, 2026, by Corcept Therapeutics Incorporated, a Delaware corporation. The filing reports a material event under Item 8.01 (Other Events) regarding the company's drug development pipeline.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory milestone rather than financial performance.
Material Changes and Events
- Regulatory Submission: On June 17, 2026, the Company resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA).
- Product: The application is for relacorilant.
- Indication: The drug is intended as a treatment for patients with Cushing's syndrome.
Guidance, Outlook, and Risks
The filing incorporates a press release (Exhibit 99.1) by reference but does not contain explicit management commentary, financial guidance, or a detailed risk assessment within the text of the 8-K itself. The resubmission of the NDA implies a prior regulatory interaction, though the specific reasons for the resubmission are not detailed in this summary text.
Investor Verification Checklist
- Review the attached Press Release (Exhibit 99.1) for details on the reasons for the NDA resubmission and the expected FDA review timeline.
- Verify the status of the previous NDA submission for relacorilant to understand the context of this resubmission.
- Monitor upcoming FDA communications regarding the acceptance and review of the resubmitted application.
- Check subsequent filings for any updates on the company's cash position, as clinical development and regulatory processes are capital intensive.